Cosentyx (secukinumab) — United Healthcare
moderate to severe plaque psoriasis
Initial criteria
- Diagnosis of moderate to severe plaque psoriasis
- Patient is not receiving Cosentyx in combination with another targeted immunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia (certolizumab), Enbrel (etanercept), Ilumya (tildrakizumab), Olumiant (baricitinib), Otezla (apremilast), Simponi (golimumab), Orencia (abatacept), Rinvoq (upadacitinib), Siliq (brodalumab), Skyrizi (risankizumab), Sotyktu (deucravacitinib), Stelara (ustekinumab), Taltz (ixekizumab), Tremfya (guselkumab), Xeljanz (tofacitinib)]
Reauthorization criteria
- Documentation of positive clinical response to Cosentyx therapy
- Patient is not receiving Cosentyx in combination with another targeted immunomodulator [same list as above]
Approval duration
12 months